Canmab 440 Mg Inj

BIOCON LTD

PACKING : 1 VIAL

GENERIC NAME : TRASTUZUMAB

Biocon Ltd, the leading biotech company in Asia, presented CANMAb ™ (150 mg / 440 mg), a trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb ™, developed jointly by Biocon and Mylan as part of a global partnership, is set up for the benefit of patients in India.

What is it used for?

Breast cancer is the most prevalent cancer among Indian women before cervical cancer and CANMAb ™ will offer a quality and more affordable option to breast cancer patients in India. About 1.5 lakh new patients are diagnosed with breast cancer each year in India, of which nearly 25% of cases are HER2-positive and eligible for treatment with CANMAb ™. The lack of affordable treatment options has limited the extent of HER2 testing and it is believed that the proportion of HER2-positive patients is likely to be higher.

Kiran Mazumdar-Shaw, President and CEO, Biocon Ltd, said: “Biocon intends to make a significant difference in the paradigm of treatment for HER2-positive breast cancer in India by improving access to treatment more affordable with CANMAb ™ (trastuzumab), which provides the same level of safety and efficacy as the reference product. The launch of CANMAb ™ in India is an important milestone for our biosimilators program and demonstrates our ability to deliver on our promise affordable innovation with a quality product and high quality. ”

CANMAb ™ is a targeted therapy for the treatment of HER2-positive breast cancer and works by interfering with the production of HER2 proteins and stopping the growth of cancer cells. It is easy to administer and will be administered intravenously, once every 3 weeks or every week depending on the condition of the patient. Unlike the currently available product on the market, Trasuzumab 150 and 440 mg formulations can be stored for 1 month, which is an important offer for patients in India, as this will ensure that there is no dosage or fairly common drug waste today.